Orexo appoints Peter Edman as Chief Scientific Officer

Orexo appoints Peter Edman as Chief Scientific Officer

Uppsala, Sweden, October 4, 2011 - Orexo AB (STO: ORX) appoints Peter
Edman as Chief Scientific Officer. Peter Edman's long experience from
all phases of drug development and his extensive scientific background
makes him particularly well suited for assuming the overall
responsibility for Orexo's research and development.

Peter Edman holds a PhD and Associate Professor title in Biochemistry
and has since 2008 been Chief Scientific Officer/Head of Research and
Development at Sobi (Swedish Orphan Biovitrum). Prior to joining Sobi,
Peter held various positions within research and development at
Pharmacia, Astra och AstraZeneca. He has also been Director at the
Swedish Medical Product Agency and has a background as Professor in
Pharmaceutical Formulation and Adjunct Professor in drug delivery at the
Faculty of Pharmacy, Uppsala University.

"It will be very exciting and rewarding to develop Orexo's projects into
innovative new drugs that can address significant medical needs," said
Peter Edman.

"Peter Edman has extensive experience in the areas of research and
development and leadership. Both his skills in early drug discovery and
drug development in late stages will be of great value to Orexo. The
strengthening of the executive management is the next step in our
strategy to create profitability focusing on our three proprietary
programs," said Anders Lundström, President and CEO of Orexo. "I am
pleased to welcome Peter to Orexo's executive management team."

Peter Edman will assume his position on January 1, 2012.

For further information, please contact:
Anders Lundström, President and CEO, Orexo AB
Tel: +46 706 67 22 66
E-mail: anders.lundstrom@orexo.com (anders.lundstrom@orexo.com)

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. The company has four commercialized products,
several projects developed in partnership as well as three proprietary
development programs. Orexo's registered products are Abstral® for the
treatment of breakthrough cancer pain, sold by Kyowa Hakko
Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill
Edluar™, sold by Meda in the USA, as well as two products for the
diagnosis of Helicobacter pylori which are being marketed by the
subsidiary Kibion. More information can be found at
www.orexo.com (http://www.orexo.com/).

Note
Orexo AB (publ) discloses the information provided in this press release
pursuant to the Securities Markets Act. The information was provided for
public release on October 4, 2011 at 09:00a.m. CET. This press release
has been prepared in both Swedish and English. In the event of any
discrepancy in the content of the two versions, the Swedish version
shall take precedence.